Please try another search
For the nine months ended 30 September 2018, IDL Biotech AB revenues decreased 22% to SEK19.4M. Net loss totaled SEK3.6M vs. income of SEK577K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Personnel Expenses increase of 14% to SEK10.8M (expense), Depreciation/Amortization increase of 2% to SEK841K (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 6.92 | 7.01 | 5.47 | 7.3 |
Gross Profit | 3.17 | 2.57 | 2.29 | 3.01 |
Operating Income | -0.43 | -1.34 | -1.58 | -0.42 |
Net Income | -0.5 | -1.45 | -1.64 | -0.48 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 16.4 | 15.68 | 18.78 | 18.13 |
Total Liabilities | 12.58 | 11.36 | 11.29 | 10.73 |
Total Equity | 3.82 | 4.31 | 7.49 | 7.4 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.21 | 0.46 | 1.72 | 0.5 |
Cash From Investing Activities | -0.29 | -0.19 | -0.06 | -0.49 |
Cash From Financing Activities | 0.43 | -0.25 | 0.34 | 0 |
Net Change in Cash | -0.07 | 0.02 | 2 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review